Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELU NASDAQ:ENVB NASDAQ:PASG NASDAQ:QUCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELUCelularity$0.62-6.8%$0.89$0.57▼$4.35$17.95M0.48143,677 shs222,078 shsENVBEnveric Biosciences$1.42+10.5%$2.44$1.26▼$17.64$5.21M1.11213,373 shs209,524 shsPASGPassage Bio$4.70+8.5%$5.65$3.29▼$20.00$15.08M1.41128,647 shs279,266 shsQUCYMainz Biomed$1.63+12.4%$1.70$0.30▼$4.93$23.90M2.224.61 million shs65.46 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELUCelularity0.00%-17.59%-37.44%-49.18%-67.02%ENVBEnveric Biosciences0.00%+10.55%-39.01%-24.73%-90.49%PASGPassage Bio0.00%-15.92%-17.69%-26.33%-27.91%QUCYMainz Biomed0.00%-7.39%-45.30%+270.45%+162,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELUCelularity$0.62-6.8%$0.89$0.57▼$4.35$17.95M0.48143,677 shs222,078 shsENVBEnveric Biosciences$1.42+10.5%$2.44$1.26▼$17.64$5.21M1.11213,373 shs209,524 shsPASGPassage Bio$4.70+8.5%$5.65$3.29▼$20.00$15.08M1.41128,647 shs279,266 shsQUCYMainz Biomed$1.63+12.4%$1.70$0.30▼$4.93$23.90M2.224.61 million shs65.46 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELUCelularity0.00%-17.59%-37.44%-49.18%-67.02%ENVBEnveric Biosciences0.00%+10.55%-39.01%-24.73%-90.49%PASGPassage Bio0.00%-15.92%-17.69%-26.33%-27.91%QUCYMainz Biomed0.00%-7.39%-45.30%+270.45%+162,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELUCelularity 2.00Hold$6.00867.74% UpsideENVBEnveric Biosciences 1.00SellN/AN/APASGPassage Bio 2.11Hold$13.25181.91% UpsideQUCYMainz Biomed 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest ENVB, QUCY, CELU, and PASG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026PASGPassage Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/10/2026PASGPassage Bio UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral6/10/2026PASGPassage Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/11/2026QUCYMainz Biomed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/27/2026QUCYMainz Biomed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026ENVBEnveric Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PASGPassage Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy ➝ Neutral$21.00 ➝ $7.004/21/2026PASGPassage Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$21.00 ➝ $7.004/21/2026PASGPassage Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$30.00 ➝ $15.004/21/2026PASGPassage Bio TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/21/2026PASGPassage Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$32.00 ➝ $8.00(Data available from 6/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELUCelularity$26.55M0.68N/AN/A($1.32) per share-0.47ENVBEnveric BiosciencesN/AN/AN/AN/A$7.00 per shareN/APASGPassage BioN/AN/AN/AN/A$5.90 per shareN/AQUCYMainz Biomed$540K44.25N/AN/A$0.07 per share23.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELUCelularity-$91.72M-$3.33N/AN/AN/A-345.45%N/A-77.94%8/12/2026 (Estimated)ENVBEnveric Biosciences-$8.77M-$23.54N/AN/AN/AN/A-220.97%-177.47%8/17/2026 (Estimated)PASGPassage Bio-$45.52M-$11.84N/AN/AN/AN/A-150.88%-59.78%7/30/2026 (Estimated)QUCYMainz Biomed-$16.21M-$47.60N/AN/AN/AN/AN/AN/AN/ALatest ENVB, QUCY, CELU, and PASG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ENVBEnveric BiosciencesN/A-$1.08N/A-$1.08N/AN/A5/12/2026Q1 2026PASGPassage Bio-$2.7640-$2.36+$0.4040-$2.36N/AN/A4/30/2026Q4 2025CELUCelularityN/A-$0.85N/A-$0.85N/A$4.10 million3/31/2026Q4 2025QUCYMainz BiomedN/A-$0.0250N/A-$0.0250N/A$0.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCELUCelularityN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/AQUCYMainz BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELUCelularityN/A0.150.15ENVBEnveric BiosciencesN/A11.6611.66PASGPassage BioN/A1.731.73QUCYMainz BiomedN/A2.112.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELUCelularity19.02%ENVBEnveric Biosciences13.82%PASGPassage Bio53.48%QUCYMainz BiomedN/AInsider OwnershipCompanyInsider OwnershipCELUCelularity17.30%ENVBEnveric Biosciences2.41%PASGPassage Bio4.90%QUCYMainz Biomed3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELUCelularity22028.95 million23.94 millionOptionableENVBEnveric Biosciences203.68 million3.59 millionNot OptionablePASGPassage Bio1303.21 million3.05 millionNo DataQUCYMainz Biomed3014.66 million14.21 millionN/AENVB, QUCY, CELU, and PASG HeadlinesRecent News About These CompaniesQuantum Cyber jumps 24% on plans to acquire strategic stake in SpaceXJune 26 at 11:21 AM | invezz.comIQuantum Cyber Approves Acquisition of Equity Stake in SpaceXJune 26 at 8:00 AM | globenewswire.comQuantum Cyber Announces Compliance With Trump Administration's National Quantum Initiative Executive Order Following Washington D.C. Delegation and Capitol Hill EngagementsJune 24, 2026 | globenewswire.comQuantum Cyber Unveils Quantum Station: A Battlefield Operating System for Multi-Domain Autonomous WarfareJune 23, 2026 | globenewswire.comQuantum Cyber Issues Letter to ShareholdersJune 22, 2026 | globenewswire.comCorrection: Quantum Cyber Executes Exclusive Quantum Antenna License Agreement, Positoning the Quantum Technology Layer at the Core of Its Defense PlatformJune 15, 2026 | globenewswire.comQuantum Cyber Executes Exclusive Quantum Antenna License Agreement, Positoning the Quantum Technology Layer at the Core of Its Defense PlatformJune 15, 2026 | globenewswire.comQuantum Cyber Terminates At-the-Market Facility, Citing Strengthened Financial Position and No Immediate Capital NeedsJune 12, 2026 | globenewswire.comQuantum Cyber Entering Steady-State Scale Production, Launches Vertically Integrated Advanced Filament Manufacturing DivisionJune 11, 2026 | globenewswire.comQuantum Cyber Signs LOI to Acquire an Estimated 43,000 Square Foot U.S.-Based Manufacturing Facility to Support Mass-Scale Autonomous Drone ProductionJune 8, 2026 | globenewswire.comQuantum Cyber Publishes Inaugural Corporate Investor Presentation Showcasing System-of-Systems Autonomous Defense Platform, Eight Filed Patent Positions, LOIs With General Cherry and SOCOM, and $15 Million Debt-Free Balance SheetJune 3, 2026 | globenewswire.comQuantum Cyber Assumes Direct Manufacturing of Autonomous Drone; Expands BP United AgreementJune 2, 2026 | globenewswire.comQuantum Cyber Announces Plans to Establish U.S.-Based Defense-Technology Manufacturing Complex to Support Drone and Autonomous Systems DeliveryMay 28, 2026 | globenewswire.comQuantum Cyber Files Provisional Patent Application for Coaxial Dual-Propellant Grain Solid Rocket Motor Designed to Extend Range and Loiter Time of Defense UAVsMay 27, 2026 | globenewswire.comQuantum Cyber Strengthens Balance Sheet with Over $15 Million in Aggregate Financing; Cap Table is Debt-FreeMay 26, 2026 | globenewswire.comQuantum Cyber Files Provisional Patent with USPTO for Integrated Swarm Defense for Autonomous Ground VehiclesMay 21, 2026 | globenewswire.comQuantum Cyber Files Provisional Patent for Quantum-Navigated Amphibious Autonomous Ground Vehicle PlatformMay 20, 2026 | globenewswire.comQuantum Cyber Files Non-Provisional Patent Application With the USPTO for EMP-Shielding 3D-Printable Composite Filament for Drone and Defense ElectronicsMay 19, 2026 | globenewswire.comQuantum Cyber Files Patent with USPTO for Autonomous Naval Mine Countermeasure System Addressing Iran's Mining of the Strait of Hormuz and Trump Administration Homeland Security PrioritiesMay 19, 2026 | globenewswire.comQuantum Cyber forms US defense subsidiary for drone programsMay 19, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENVB, QUCY, CELU, and PASG Company DescriptionsCelularity NASDAQ:CELU$0.62 -0.05 (-6.81%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$0.69 +0.07 (+11.29%) As of 06/26/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Enveric Biosciences NASDAQ:ENVB$1.42 +0.14 (+10.55%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$1.40 -0.01 (-0.99%) As of 06/26/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Passage Bio NASDAQ:PASG$4.70 +0.37 (+8.55%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$4.56 -0.14 (-2.98%) As of 06/26/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Mainz Biomed NASDAQ:QUCY$1.63 +0.18 (+12.41%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$1.51 -0.12 (-7.30%) As of 06/26/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
